Rhumbline Advisers Sells 650 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Rhumbline Advisers cut its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 0.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 91,939 shares of the biopharmaceutical company’s stock after selling 650 shares during the period. Rhumbline Advisers owned 0.14% of Celldex Therapeutics worth $2,323,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Values First Advisors Inc. increased its position in shares of Celldex Therapeutics by 20.0% during the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company’s stock valued at $733,000 after buying an additional 4,837 shares during the period. Sovran Advisors LLC bought a new stake in shares of Celldex Therapeutics during the fourth quarter valued at about $2,867,000. KBC Group NV increased its position in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 1,647 shares during the period. SG Americas Securities LLC increased its position in shares of Celldex Therapeutics by 24.4% during the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company’s stock valued at $639,000 after buying an additional 4,967 shares during the period. Finally, Mirador Capital Partners LP increased its position in shares of Celldex Therapeutics by 2.9% during the fourth quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company’s stock valued at $3,020,000 after buying an additional 3,345 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on CLDX shares. UBS Group started coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $56.50.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $20.57 on Monday. The firm has a market cap of $1.36 billion, a P/E ratio of -8.00 and a beta of 1.60. The stock has a 50 day simple moving average of $23.86 and a two-hundred day simple moving average of $28.89. Celldex Therapeutics, Inc. has a 1 year low of $19.83 and a 1 year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.